Pancreatic Cancer Data Is Creating Billions in Value - This Multi-Cancer Platform Could Be Next (NASDAQ: DRTS)
A localized radiation platform is showing early clinical promise in pancreatic and other cancers, with a major conference presentation approaching.
On April 13, Revolution Medicines (NASDAQ: RVMD) reported that its oral drug daraxonrasib nearly doubled median overall survival in a Phase 3 metastatic pancreatic cancer trial. The stock surged sharply, pushing the company’s market capitalization toward $30 billion and adding billions in value. Within days, Revolution raised $2.2 billion in a public offering to fund commercialization.
Pancreatic cancer carries a five-year survival rate of roughly 13% and has resisted nearly every therapeutic approach for decades. Daraxonrasib targets RAS mutations, found in about 90% of pancreatic cancers and long considered “undruggable.” It is a systemic therapy, circulating through the body to reach cancer cells wherever they are. Increasingly, oncology treatment strategies are exploring combinations of systemic therapies with localized approaches directed at the tumor itself. That is where Alpha Tau Medical (NASDAQ: DRTS) comes in.
The company is developing Alpha DaRT, a localized radiation therapy that has shown early signs of shrinking or stabilizing pancreatic tumors while preserving key immune markers—an outcome that could be relevant for future combination approaches, though further study is needed.
Radiation That Stays Where It’s Needed
Alpha DaRT places small radium-224-containing sources directly into the tumor. As the radium decays, its short-lived radioactive daughter atoms diffuse a few millimeters through the tumor before releasing alpha particles, concentrating destructive energy inside the tumor while largely sparing surrounding healthy tissue.
In the most recent final dataset from Alpha Tau’s first-in-human pancreatic trial in Montreal, presented at ASCO GI 2026 in January, 81% of the 32 patients treated had tumors that shrank or stopped growing, rising to 87% when excluding the first two patients, who received reduced doses during initial safety testing. Tumors measurably shrank in 22% of patients. Every procedure was successfully completed.
Researchers also tracked whether treatment was harming patients’ immune systems, a common side effect of conventional radiation. Key immune indicators remained stable one month after treatment, and IL-6, a protein typically associated with inflammatory response, declined significantly.
These findings are early, but they suggest the potential for a localized therapy that may avoid some of the systemic immune suppression associated with traditional radiation.
A Platform Approach Across Multiple Cancers
What distinguishes Alpha Tau from most early-stage oncology companies is breadth. Alpha DaRT is not a molecule designed for one mutation or one cancer type. It is a physical mechanism—localized alpha-particle radiation—that the company is testing across multiple solid tumors.
Alpha Tau currently has multiple FDA-authorized clinical trials in the United States across several cancer types, including skin cancer (cutaneous squamous cell carcinoma), pancreatic cancer, glioblastoma, and prostate cancer.
In head and neck cancer, a small combination trial pairing Alpha DaRT with Merck’s pembrolizumab showed a 75% systemic objective response rate in the first eight patients. The company has compared this to historical pembrolizumab monotherapy benchmarks from trials such as KEYNOTE-048, though cross-trial comparisons should be interpreted cautiously given the small sample size and early-stage nature of the data.
In February, Japan’s Ministry of Health granted Shonin marketing approval for Alpha DaRT in unresectable head and neck cancer, marking the platform’s first marketing approval outside Israel. The U.S. FDA has granted Breakthrough Device Designation for multiple indications, including recurrent skin cancer, recurrent glioblastoma, and oral cavity cancers. The company has also submitted the first module of its pre-market approval (PMA) application to the FDA for skin cancer.
An Upcoming Pancreatic Cancer Catalyst
On March 31, Alpha Tau announced that updated results from its two Jerusalem pancreatic trials were accepted for an oral presentation at Digestive Disease Week (DDW) 2026, a major international gastroenterology conference. The presentation is scheduled for May 2.
While the data has not yet been presented, oral presentations at major medical conferences are often reserved for findings considered to be of particular interest, and the upcoming DDW presentation may provide additional context around the company’s growing pancreatic cancer dataset.
The Takeaway
Revolution Medicines demonstrated that meaningful progress against pancreatic cancer can translate into substantial market value creation.
Alpha Tau, with a market capitalization of roughly $700 million, is generating clinical data across multiple tumor types, with a first marketing approval secured and several regulatory designations from the FDA.
The data is early. These are first-in-human studies, not Phase 3 registrational trials. But the clinical signals across multiple cancers, the immune-related findings, and the upcoming DDW presentation suggest a company approaching a potentially important inflection point.
Read this next >> The Long-Acting Challenger: What Spyre's Phase 2 Win Means for the Future of IBD Treatment
Recent news highlights from Alpha Tau
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. The content above is a form of paid promotional content and advertising. Wall Street Wire receives cash compensation from Alpha Tau Medical Ltd or a related party for ongoing coverage and awareness services. This content is for informational purposes only and does not constitute financial or investment advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: http://wallstwire.ai/disclosures. Market size figures or other estimates referenced in this article are quoted from publicly available sources; we do not independently verify or endorse them, and additional figures or estimates may exist. This article should not be considered an official communication of the issuer.
